Ergocalciferol supplementation in children with CKD delays the onset of secondary hyperparathyroidism: a randomized trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc in the context of hyperparathyroidism.

The hypothesis was that nutritional vitamin D (ergocalciferol) supplementation in children with CKD stages 2-4 delays the onset of secondary hyperparathyroidism.

Who Took Part

By PubMed's age tags, the people studied were young children, children and teenagers, both men and women.

A randomized, double-blinded, placebo-controlled study in children with CKD2-4 who had 25-hydroxyvitamin D [25(OH)D] deficiency was conducted.

The primary endpoint was the time to development of hyperparathyroidism.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

What Was Measured

Topics PubMed links to this paper include Analysis of Variance, Biomarkers, Chi-Square Distribution, Chronic Disease, Dietary Supplements, Ergocalciferols and Hyperparathyroidism, Secondary.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in people with hyperparathyroidism.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2012 (Clinical journal of the American Society of Nephrology : CJASN), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Hyperparathyroidism research.